SyntheticGestalt is pleased to announce that its research has received the Excellent presentation award at the CBI Society 2023 annual conference, held at Tower Hall Funabori, Tokyo, in the period 23rd ~ 26th October, 2023.
The research in question proposes a method for a data split that more accurately measures performance of a model on unlabelled data with a known distribution to tackle the problem of performance discrepancies between test data and actual operation. This method addresses a well established issue in the application of machine learning to the field of drug discovery.
The details of the award can be found in the link below:
https://cbi-society.jp/files/annual-meetings/2023/OralExcellentPresentationAward.pdf
The CBI Society is a non-profit academic organisation that aims to build a foundation for advanced research and development in the three academic fields of Chemistry, Biology and Informatics. The 2023 conference was held under the theme 'Next-generation healthcare pioneered by large-scale data: new drug discovery and medical care using genome and clinical data'.
SyntheticGestalt is an artificial intelligence research and development company specialising in AI drug discovery and other life science fields. Its research and development is focused around the discovery of useful substances using its independently developed artificial intelligence technology. The AI platform used in this research has a cloud-based, scalable structure and can make predictions on large libraries, making it possible to predict pharmacokinetics, physicochemicals and early toxicity. SyntheticGestalt welcomes open innovation through joint research with public institutions and private companies.